Stay updated with breaking news from Time Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia and the May 2021 approval of Janssen's...
/PRNewswire/ -- Following the May 2021 FDA approval of Biohaven's Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs)...
/PRNewswire/ -- Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and...
Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients. The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia...
Share this article Share this article EXTON, Pa., Feb. 17, 2021 /PRNewswire/ -- Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis' Cosentyx and Eli Lilly's Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherix's RealTime Dynamix ™ service, the official entrance of the IL-17 inhibitors is causing a shift in the market where UCB's Cimzia previously held the position as the only biologic with commercial avail...